Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Related Keywords

United States ,Russia ,Japan ,Ukraine ,Edna Kaplan ,Daniel Vitt ,Jessica Breu ,Paula Schwartz ,Prnewswire Immunic Inc ,Nasdaq ,Immunic Inc ,Rx Communications Group ,Trademark Office ,Exchange Commission ,Fundamental New Patent Covers Treatment ,Multiple Sclerosis Into ,Vidofludimus Calcium ,Multiple Sclerosis ,Unless Extended Further ,Protecting Specific Dose Strength ,Relapsing Multiple Sclerosis Treatment ,United States Patent ,Dosage Regimen ,Chronic Inflammatory ,Autoimmune Diseases ,Patent Term Extension ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Middle East ,Annual Report ,Investor Relations ,Immunic ,Nc ,